Jubbonti

Showing 1 posts of 1 posts found.

FDA approves Sandoz’s denosumab biosimilars

March 6, 2024
Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab

Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …

Latest content